Search Results
Update on bb2121 for relapsed myeloma
Updated Results of the Idecabtagene Vicleucel (ide-cel bb2121) CRB-401 Trial in RR Multiple Myeloma
Update on bb2121 CAR T-cell product for MM from EHA 2018
ide-cel; bb2121, a BCMA-targeted CAR T-cell therapy, in patients with RRMM: Initial KarMMa results
Idecabtagene Vicleucel in Pts with Relapsed and Refractory Multiple Myeloma: Updated KarMMa Results
An Overview of a Study of bb2121 in Multiple Myeloma
Therapy of relapsed multiple myeloma - An update
Dr. Berdeja Discusses Results for bb2121 in Multiple Myeloma
Dr. Berdeja Discusses Next Steps With bb2121 in Multiple Myeloma
Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
Ide-cel (formerly bb2121) anti-BCMA CAR T-cell therapy in relapsed/refractory MM
Updates in Multiple Myeloma from ASCO 2020
